Dooley, K. E., Luetkemeyer, A. F., Park, J., Allen, R., Cramer, Y., Murray, S., . . . Haas, D. W. (2014). Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. American Society for Microbiology.
Citação norma ChicagoDooley, Kelly E., et al. Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 With Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. American Society for Microbiology, 2014.
Citação norma MLADooley, Kelly E., et al. Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 With Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. American Society for Microbiology, 2014.